ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, a next generation CD47 myeloid checkpoint inhibitor, is a fusion protein comprised of an engineered high affinity CD47 binding domain of SIRPα linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to maximize the clinical benefit of anti-cancer therapeutics and is in clinical development for a broad range of tumor types.

Latest News

February 18, 2020 – ALX Oncology’s ALX148 Receives Two Fast Track Designations from FDA for the Treatment of Patients with Head and Neck Squamous Cell Carcinoma and Patients with Gastric or Gastroesophageal Junction Adenocarcinoma  Read more

February 12, 2020 – ALX Oncology Announces Closing of $105 Million Series C Financing  Read more

January 7, 2020 – ALX Oncology Appoints Peter S. García as Chief Financial Officer  Read more

More